



Neuroblastoma: Molecular Insights and Clinical Implications

Guest Editor:

Dr. Mary Beth Madonna

Division of Pediatric Surgery,
Department of Surgery, Rush
University Medical Center,
Chicago, IL 60612, USA

Deadline for manuscript
submissions:

15 May 2025

Message from the Guest Editor

Dear Colleagues,

Neuroblastoma has long frustrated clinicians as it is a very heterogeneous, oftentimes aggressive cancer of childhood. It is the most common non-brain solid tumor in children, and the survival remains under 70% for most patients. Therefore, physician scientists as well as bench scientists have long sought to understand this disease in order to find better targeted therapies. The articles in this issue will focus on some of the newer treatment modalities that go beyond traditional chemotherapies and include immunotherapies and small molecule therapies. This issue is dedicated to showcasing some of the most up-to-date developments in the field. The hope is that by understanding the molecular mechanisms of neuroblastoma, we will find new targets for therapy and improve survival in children with this tumor.

Dr. Mary Beth Madonna
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)